Skip to Main Content

Castle Biosciences, Inc. Common Stock

CSTL Real Time Price USD
N/A
N/A
N/A
...
...
Overview
Financials
Forecast
Insiders
Institutions
Government
Ownership
News
Income
Balance Sheet
Cash Flow
Revenue Breakdown
CSTL Stock Insider Trading Activity Follow @QuiverQuant for major insider updates
Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
CSTL Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
CSTL Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported

Recently reported changes by institutional investors

Quarterly net insider trading by CSTL's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions
  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

schema-2

Government lobbying spending instances

  • $40,000 Jun 30, 2025 Issue: Medicare/Medicaid
  • $40,000 Apr 08, 2025 Issue: Medicare/Medicaid
  • $40,000 Jan 06, 2025 Issue: Medicare/Medicaid
  • $40,000 Oct 03, 2024 Issue: Medicare/Medicaid
  • $40,000 Jul 09, 2024 Issue: Medicare/Medicaid
  • $60,000 Apr 01, 2024 Issue: Medicare/Medicaid
  • $60,000 Jan 05, 2024 Issue: Medicare/Medicaid
  • $30,000 Oct 06, 2023 Issue: Medicare/Medicaid

Estimated quarterly lobbying spending

CSTL Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
CSTL Income Statement
CSTL Balance Sheet
CSTL Cash Flow
U.S. Patents

New patents grants

  • Patent Title: Methods of diagnosing and treating patients with cutaneous squamous cell carcinoma May. 07, 2024
  • Patent Title: Methods of diagnosing and treating patients with cutaneous squamous cell carcinoma May. 07, 2024
  • Patent Title: Diagnostic test for predicting metastasis and recurrence in cutaneous melanoma Sep. 06, 2022
  • Patent Title: Diagnostic test for predicting metastasis and recurrence in cutaneous melanoma Mar. 03, 2020
Government Contracts

Estimated quarterly amount awarded from public contracts

CSTL News

Recent insights relating to CSTL

CNBC Recommendations

Recent picks made for CSTL stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in CSTL

CSTL Analyst Ratings

CSTL Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
CSTL Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $CSTL stock a Buy, Sell, or Hold?

  • What is the price target for $CSTL stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

CSTL Top Shareholders
Shareholder
Shares Held
CSTL Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $CSTL stock?

  • Who owns the most shares of $CSTL stock?

  • What funds own $CSTL stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

CSTL Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view CSTL Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top